An Evaluation of International Contemporary Operative Outcomes and Management Trends Associated with Esophagectomy: A Four-Year Study of Over 6000 Patients Using ECCG Definitions and the Online Esodata Database

Madhan K. Kuppusamy, FRCS (C-Th) and Donald E. Low, FACS, FRCS On Behalf of the International Esodata Study Group (IESG)

List of Institutions: Agaplesion Markus Krankenhaus, Frankfurt, Germany; Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Cambridge Oesophago-Gastric Centre, Addenbrookes Hospital, Cambridge, UK; Claude Huriez University Hospital, Lille, France; Erasmus Medical Center, Rotterdam, Netherlands; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA; Guy's & St Thomas' NHS Foundation Trust, London, UK; Hirslanden Medical Center, Zürich, Switzerland; Hôpital Nord, Aix-Marseille Université, Marseille, France; Hospital Universitario del Mar, Barcelona, Spain; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Katholieke Universiteit Leuven, Leuven, Belgium; Keio University, Tokyo, Japan; Massachusetts General Hospital, Boston, MA, USA; MD Anderson Cancer Center, Houston, TX, USA; Memorial Sloan Kettering Cancer Center, New York City, NY, USA; National University Hospital, Singapore, Singapore; Newcastle Upon Tyne Hospitals, Newcastle upon Tyne, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK; Odense University Hospital, Odense, Denmark; Oregon Health and Science University, Portland, OR, USA; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Princess Alexandra Hospital, University of Queensland, Brisbane, Australia; Queen Elizabeth Hospital University of Birmingham, Birmingham, UK; Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China; Royal Victoria Hospital, Belfast, Northern Ireland; Sichuan Cancer Hospital & Institute, Chengdu, China; St. James's Hospital Trinity College, Dublin, Ireland; Tata Memorial Centre, Mumbai, India; The University of Chicago Medicine, Chicago, IL, USA; Toronto General Hospital, Toronto, Canada; University Hospital of Cologne, Cologne, Germany; University Hospital Southampton NHS Foundation Trust, Southampton, UK; University Medical Center, Utrecht, Netherlands; University of Michigan Health System, Ann Arbor, MI, USA; University of São Paulo School of Medicine, São Paulo, Brazil; University of Verona, Verona, Italy; Virginia Mason Medical Center, Seattle, WA, USA; Vita-Salute San Raffaele University, Milan, Italy

Word Count

Title:	28
Abstract:	269
Paper w/o Tables:	4694

Running Head: Esophagectomy outcomes Esodata database

CORRESPONDENCE TO:

Donald E. Low, FACS, FRCS(C), FRCSI(Hon), FRCSE(Hon), FRCSEdin(Hon)
Virginia Mason Medical Center
1100 Ninth Ave
Seattle, WA 98111
Phone: 206-223-6164
Fax: 206-625-7245
donald.low@virginiamason.org

INTRODUCTION

Major complications following esophageal cancer surgery are associated with increased operative mortality,[1-3] cancer recurrence, diminished long-term survival,[4-8] longer hospital stay,[8-10] more readmissions,[11-14] greater hospital costs,[15,16] and worse long-term health-related quality of life (HR-QL).[17,18] Mortality rates are best in high volume centers, but 90-day mortality remains between 2.5% and 7%, and, even in a minimally invasive era, morbidity rates are high.[3,19,20]

Until standardized and generally accepted definitions were developed by the Esophageal Complications Consensus Group (ECCG) in 2011, it was impossible to make comparisons between studies. The first internet-based international oncologic dataset (Esodata.org), has previously provided a contemporary benchmark for the incidence of perioperative esophageal outcomes including complications.[19] This has provided a validated methodology for institutions,[20] a tool for systematic reviews,[9] a secondary outcome data set used within international randomized clinical trials (RCTs),[21] and national datasets[22] as well as an infrastructure for comparative national and international audits, thereby supporting the development of quality improvement programs.

An ECCG publication on benchmarks comprehensively documented all perioperative complications as well as 30- and 90-day mortality in 2,704 resections from 24 high volume centers representing 24 countries collected over a two-year period between January 2015 and December 2016.[19] The report herein expands this dataset to over 6000 patients, with the primary aim of the present study to compare outcomes, including rates of four specific complications (anastomotic leak, conduit necrosis, recurrent laryngeal nerve injury, chyle leak) between the original ECCG dataset (January 2015-December 2016) to a more recent two-year period

(January 2017- December 2018). Secondary goals included reporting on recommended quality improvement measures developed by the ECCG[23] (90-day mortality rate, 30-day readmission rates, requirement for documenting change/escalation in level of care, blood product utilization (quantity and timing) and documentation of discharge location). This study will also assess the utility of an internet-based high volume international standardized dataset to document short-term evolution in patient and tumor demographics, operative technique, mandatory quality measures as well as individual complication incidence and overall complication severity.

METHODS

The Esodata dataset, based on the standardized platform developed by the ECCG,[23] was initiated as a secure, web-based database in March 2015. The original 24 centers of the ECCG committed to entering all esophageal resections done at their institution starting in January 2015 (see Membership Agreement Supp1). Data was collected from these 24 centers until December 2016 when the preliminary benchmark of complications was published.[19]

Over the subsequent year, 15 additional high volume international esophagectomy centers applied and were admitted to the International Esodata Study Group (IESG), so currently there are 39 centers representing 19 countries (Table 1). All centers were responsible for complying with institutional and national ethics and IRB requirements and the dataset remained in a format where all patient information within the database was anonymized to comply with international data privacy agreements.

The original Esodata dataset was designed using the consensus-based data fields and definitions agreed by the ECCG, and only registered contributors from participating institutions could enter patients into the database. The data collection process via a secure web interface was

constructed using a standardized “user-friendly” online database platform to encourage not only compliance with entering all esophageal resections but also encouraging data completeness and integrity. In the context of the wide variation in computer systems between the 39 participating centers, the integrity and security of the dataset was guaranteed by utilizing a modern web browser based interface using encrypted network communications. In addition, pre-existing computer systems did not require institutional IT support or the downloading of complex software systems onto individual institutional hard drives. The dataset is available to surgeons, data managers and cancer coordinators through a secure sign-on at any location that they had internet connections allowing encrypted network communications. The dataset was constructed with a database interface using multiple level data validation algorithms that allowed only targeted data to be submitted.

The database and web portal were hosted, as previously described,[19] in a private dedicated web server and database interface that was accessible only through an authenticated and encrypted secure network connection (SSL Client and Server Certificate with Extended Validation issued by Symantec Corporation, Mountain View, CA). Open-source database server package (MariaDB V10.1.21 by MariaDB Foundation, Redwood City, CA) with regular encrypted backup system arrangements in combination with Drupal Content Management System (Distributed under the terms of GNU General Public License) was used for user and data access management. The system as originally designed provided portability, dynamic live data analytics, modularity and flexibility in content access management. The registered data contributors from each institution were authenticated individually to access the database interface in the members-only area of the Esodata.org web portal. Importantly, registered

contributors had instant access to their own institutional results on the Esodata website that was available to them anywhere in the world where secure internet access was available.

Statistical Methods

The cohort was stratified according to time period of inclusion. Comparisons between the groups were done using Chi-square test. Quantile regression model was used to analyze the association between grade of anastomotic leak, conduit necrosis, recurrent laryngeal nerve injury, and chyle leak to Clavien-Dindo score and length of hospital stay. Significance level was set at 0.05. Analyses were performed using STATA® version 13 software (StataCorp LP, College Station, Texas, USA).

RESULTS

Outcome Analysis of Entire Study Population (2015-18)

The current study population includes 6,022 patients entered into the Esodata dataset between January 2015 and December 2018. Patient demographics are shown in Table 2. The majority were male (78.3%), with a mean age of 63.2 years. Patients presented with a BMI >30 in 20.5% of cases, and 5.4% had a BMI <18.5. ASA II was most common, reported in 44.3%, with ASA III at 40.0% and ECOG 0/1 in 93.9%. Most tumors were located in the distal esophagus (54.4%) or at the esophagogastric junction (33.8%). Minimally invasive esophagectomy (MIE) surpassed open cases, at 52.8% vs. 47.2% cases, respectively, and 53.1% of MIE cases were accomplished with MI approaches in both abdomen and thorax (Table 3). A

transhiatal esophagectomy (THE) represented 21.5% of open cases. Neoadjuvant chemoradiation was the more common approach at 63.5% of patients undergoing neoadjuvant therapy.

For key complications (Table 4), anastomotic leak was observed in 12.5%, pneumonia in 13.9%, atrial dysrhythmia in 14.7%, chyle leak in 4.6%, delirium in 3.7%, and generalized sepsis in 2.2%. Thirty-day mortality was 2.2%, and 90-day mortality 4.5%; 39.5% of patients had no complications, and 32.3% had ≥2 complications (Table 5). For severity of complications as per Clavien-Dindo (Table 5), Grade III/IV was 30.2%, and IIIB/IV was 15.0%.

Comparison of 2015-16 with 2017-18

Demographic changes from Period 1 (2015-16) to Period 2 (2017-18) included increases in ASA III, 35% to 44% and decreases in BMI >30, 20.9% to 20.3% and BMI <18.5, 6.8% to 4.2%. In Period 2, MIE had increased significantly at 56.7% compared with 48.0% in Period 1 ($p<0.001$). A surgery-first approach decreased from 22.4% to 19.7%, and neoadjuvant chemoradiation as a percentage of the total having neoadjuvant therapy increased from 60% to 68.6% (Table 3).

Table 4 provides a comprehensive review of overall incidence of complications in the entire study group and an assessment of changes in complication incidence between the two study periods. Anastomotic leaks increased from 11.7% to 13.1% ($p=0.121$). Pneumonia decreased from 15.3% to 12.8% ($p=0.005$), and atrial dysrhythmia was 14.8% and 14.7%, respectively. Ninety-day mortality was 4.4% and 4.6% in Period 1 and 2, respectively. Acute renal failure requiring dialysis decreased from 1.0% to .4% ($p=0.004$). Grade IIIb/IV complications was 14.9% vs 15.09%.

Table 5 demonstrates that the overall incidence of complications increased from 59% to 61.1%. There was a significant decrease in the number of patients sustaining more than 3 complications from 18.0% to 15.3%. Table 5 also demonstrates changes in Clavien-Dindo severity scores with the incidence of Grade I and Grade II complications increasing, however without a significant change in the incidence of complications graded IIIb or higher. Length of hospital stay decreased slightly between the two study periods 17.3 to 16.7 days.

Quality Metrics

ECCG Quality Measures are documented in Table 6. There was no significant change in 30- or 90-day mortality between the two study periods. Readmissions within 30 days of discharge was 9.7% overall, decreased from 11.1% to 8.5%, ($p<0.05$). Blood transfusion rates decreased from 14.3% to 10.2% ($p<0.001$). Escalation in level of care defined as a change in patient location due to the need for a higher level of monitoring of care, e.g., Ward to ICU, decreased from 24.5% to 20% ($p<0.001$). Patients requiring escalation in care most commonly had pneumonia (25.9%) and atrial dysthymia (21.2%). Conversely, 41.1% of patients with pneumonia and 31.8% who had atrial dysrhythmia required an escalation of their care during their hospitalization. The percentage of patients who were discharged home decreased from 91.4% to 87.8% ($p<0.001$).

The specific definitions, incidence, severity stratification, and trends over time of the four major complications of anastomotic leak, conduit necrosis, recurrent laryngeal nerve injury, and chyle leak are shown in Table 7. Although anastomotic leak rate increased, patients requiring surgical interventions decreased from 3.3% to 3.0% in these successive periods ($p=0.087$). The incidence of conduit necrosis remained stable throughout the study period at 1.2%. The

incidence of recurrent nerve injury was unchanged with Type IIIa and IIIb being rare at 0.1% and 0.2%, respectively. The incidence of chyle leak decreased from 5.1% to 4.3% but most of this decrease was seen in patients with Type I leaks that required only dietary modifications. A significant increase was noted in Type IIIb leaks, involving high output (>1L) and surgical treatment, from 0.6% to 1.2% (p=0.026).

DISCUSSION

This study has demonstrated that a secure online standardized dataset provides a viable method for not only benchmarking esophagectomy outcomes, but also monitoring the evolution in technical approach, perioperative outcomes and quality measures.

The last two decades has witnessed increased utilization of national administrative datasets across a wide range of diseases. However, the utilization of these datasets for answering specific clinical questions has limitations, specifically in the area of directing or grading quality of performance improvement projects, and benchmarking.[24-26] Participation in national disease or procedure non-specific outcomes datasets has not routinely been associated with improving institutional clinical outcomes over time.[24] It is likely, however, that institutional improvements are better facilitated in "made for purpose" voluntary datasets. The ECCG dataset within Esodata.org may represent one such exemplar with standardized reporting platforms, specific outcome definitions and quality measures which can be monitored over time and compared to published benchmarks.[19]

One objective of this study was to provide a real-time contemporaneous report from over 6000 cases, assembled from predominantly high volume academic medical centers globally. It highlights that 90-day mortality remains between 4 and 5%, and that pneumonia, atrial

fibrillation and anastomotic leak are the commonest index complications. However, the main object of this study was to compare two consecutive study periods. This assessment demonstrates that the complexity of patients is increasing, reflected by higher ASA and ECOG scores. Obesity levels in a global network were 20%, and undernutrition, with a BMI <18.5, has significantly decreased, perhaps a reflection of a greater focus as per ERAS[27] and NCCN Guidelines.[28]

The study confirms that MIE has established itself globally, now surpassing open approaches, and where MIE is undertaken it is completely minimally invasive in over 50% of cases. Pneumonia occurring in association with esophageal resection has been a particularly important outcome measure and has been directly related to increased costs,[15] increased incidence of perioperative mortality[29] and readmissions[11,12,28,30] as well as a decrease in overall five-year survival rates.[7,29] Pneumonia rates significantly decreased between the two study periods. Whether this relates to the increasing application of MIE is not yet clear and requires further analysis, although a reduction in pneumonia and major respiratory complications was seen in the TIME, MIRO and ROBOT RCTs.[31-33] Other factors may include increased application of early mobilization programs within ERAS, as well as targeted pre-habilitation and postoperative care pathways to prevent respiratory complications.[27]

In contrast to decreasing pneumonia rates, atrial fibrillation rates remained stable, while anastomotic leaks demonstrated an increase from 11.7% to 13.1%. These results are consistent with a recent meta-analysis,[34] and also published trends associated with MIE.[35] Despite this increase, the most severe leaks requiring surgery were unchanged, an important quality metric as the severity of leaks is a major determinant of operative mortality.[1,36] The continued documentation of anastomotic leak rates over time remains a critical issue, particularly as MIE is increasingly adopted and in light of evidence associating leaks with overall survival.[35] The study

also highlights that when comprehensively documented, that complication rates remain high, at approximately 60% and severe complications, Clavien-Dindo ≥ IIIb, occur in approximately one in seven patients.

Complications are linked to short-term (two years)[32] and long-term (10 years) HRQL,[17] and costs,[15] as well as individual surgeon wellbeing.[37] Trends in individual complication incidence over time can in some cases be explained by paralleling evolutions in perioperative management. An example would be the significant decrease in urinary tract infections seen in the current study which may be related to evolving enhanced recovery protocols recommending early removal of urinary catheters, while at the same, this same process evolution could also partially explain the increased incidence in urinary retention over the study period.

Quality measures are embedded within the Esodata Database Platform.[23] Readmission rates have historically been inaccurately or incompletely reported. The readmission rate post esophagectomy reported by NSQIP in 2015 was 10.7%,[12] whereas the same year, the SEER database documented an incidence of 18.6%.[38] During the period of 2010 and 2014, the Nationwide Readmissions Database indicated that 19.4% of patients undergoing esophageal resection in the United States required readmission.[15] Readmissions have been most commonly related to the incidence of pneumonia,[11,30] anastomotic leak[39] and have also been associated with documented decreases in overall survival[38] and increased 90-day perioperative mortality.[40] The importance of accurately documenting and following trends in readmissions over time is important as it has been recognized as is a key quality indicator which is reflected in the Centers for Medicare and Medicaid Services Readmission Reduction Program (CMS) linking the occurrence of readmissions to overall reimbursement in the United States.[41] Accordingly, the reduction in readmission rates from 12% in Period 1 to 9% in Period 2 is encouraging.

The need for blood transfusion is also an important quality measure, being directly linked to long-term survival,[42-45] tumor recurrence,[43] anastomotic leak,[36] readmissions,[30] and perioperative mortality.[43,46,47] It is now generally accepted that blood loss is a quality indicator in major oncologic procedures,[48] and both medical and technical complications have been clearly linked to intraoperative blood loss.[49] The current study documented a significant increase in the incidence of patients undergoing esophagectomy without requiring a blood transfusion at any time, from 85.8% to 89.8% in successive periods. This may be an expression of raising thresholds for transfusion or improved surgical performance.

Escalation in level of care is rarely reported.[8] In the current study, this quality measure decreased from 24.5% to 20% over the two time periods. The two most common complications associated with escalation of care were pneumonia (25.9%) and atrial dysrhythmia (21.2%) with over 40% of the patients with pneumonia requiring an escalation in care at some point in their postoperative recovery.

The discharge location for patients after esophageal resection is an important quality measure because it can directly affect other quality parameters such as length of stay and readmissions. However, previous reports demonstrate that the incidence of readmissions is higher in patients who are discharged to nursing facilities.[30] The complexity of reporting results of discharge location utilizing an international dataset involves the recognition that there is significant international disparity between post-surgical discharge resources and societal expectations. In some countries in Europe, there is an historical expectation and national funding allotted for patients to spend a time at a rehabilitation facility after major oncologic surgery. This suggests that continuing to monitor international trends in discharge location remains relevant

although it is likely more pertinent to monitor changes in discharge location on a national or regional basis.

This study has some limitations. The accuracy of the data submitted by the contributing institutions has not been evaluated although all centers (Table 1) are high volume cancer centers that have routinely led and contributed to national datasets as well as participating in institutional and national research projects on esophageal cancer. Every lead investigator from contributing institutions signed the membership agreement (see Supplement 1) which required the guarantee of submitting data on all esophagectomies done in their institution, and data integrity. The composition of contributing centers highlights the obvious limitation that the outcomes reflect that of the best centers internationally and may not be indicative of general practice outcomes associated with esophageal resection. This in itself underlines the importance of the data and the key points, that complications are common, that they can be severe, and that 4 to 5% of patients will die of complications, all of this in the best performing hospitals internationally.

There are many strengths of the current study, principally the large volume of esophagectomies accumulated in a contemporary time period using standardized definitions, hence the outcomes are reflective of current international practice patterns and service delivery. The number of centers contributing to the current Esodata dataset continue to increase from the 24 international centers who contributed to the initial ECCG study in 2017[19] to 39 centers entering patients for the current study reporting on outcomes up to December 2018. The question which naturally arises regarding the current study is why the comparison of trends in outcomes was not limited to the original 24 ECCG centers. The answer includes the fact that all current contributing institutions are high volume Centers of Excellence and that the number of centers

entering data will continue to grow over time, which ultimately will make ongoing assessments of the entire dataset increasingly relevant from the international standpoint.

Since the completion of the current study, 18 additional centers have joined the International Esodata Study Group (IESG) bringing the current number of contributing centers to 57 institutions representing 19 countries with currently over 9,000 resections recorded. Other advantages of the current study reside in the fact that not only does the database have the opportunity to efficiently benchmark perioperative outcomes at a specific period of time but it clearly has the power to follow and assess trends in a wide variety of cancer-related and technical issues in addition to perioperative outcomes and quality measures. Other strengths include the secure, cloud-based series of dedicated servers, and the simplicity for data entry and the ability of institutional review from anywhere there is secure internet access.

In the future, an evolving Esodata database will enable the accurate monitoring of changes in technical trends and treatment outcomes over time, assess survival for future esophageal cancer staging systems and ultimately collect biologic and genetic data to amalgamate research efforts regarding targeted oncologic therapy. In an era of change with MIE and robotic approaches, and a focus on ERAS, this dataset will provide a vehicle to monitor this evolution and underpin safety and quality assurance.

REFERENCES

1. Linden PA, Towe CW, Watson TJ, et al. Mortality After Esophagectomy: Analysis of Individual Complications and Their Association with Mortality. J Gastrointest Surg. 2019;13:019-04346.
2. Blencowe NS, Strong S, McNair AG, et al. Reporting of short-term clinical outcomes after esophagectomy: a systematic review. Ann Surg. 2012;255:658-666.
3. Talsma AK, Lingsma HF, Steyerberg EW, et al. The 30-day versus in-hospital and 90-day mortality after esophagectomy as indicators for quality of care. Ann Surg. 2014;260:267-273.
4. Lagarde SM, de Boer JD, ten Kate FJ, et al. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71-76.
5. Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798-807.
6. Luc G, Durand M, Chiche L, et al. Major post-operative complications predict long-term survival after esophagectomy in patients with adenocarcinoma of the esophagus. World J Surg. 2015;39:216-222.
7. Booka E, Takeuchi H, Suda K, et al. Meta-analysis of the impact of postoperative complications on survival after oesophagectomy for cancer. BJS Open 2018;2:276-284.
8. Bundred JR, Hollis AC, Evans R, et al. Impact of postoperative complications on survival after oesophagectomy for oesophageal cancer. BJS Open 2020 Feb 17. doi: 10.1002/bjs5.50264. [Epub ahead of print]
9. Ozawa S, Koyanagi K, Ninomiya Y, et al. Postoperative complications of minimally invasive esophagectomy for esophageal cancer. Ann Gastroenterol Surg. 2020;4:126-134.

10. Schmidt HM, El Lakis MA, Markar SR, et al. Accelerated Recovery Within Standardized Recovery Pathways After Esophagectomy: A Prospective Cohort Study Assessing the Effects of Early Discharge on Outcomes, Readmissions, Patient Satisfaction, and Costs. Ann Thorac Surg. 2016;102:931-939.
11. Sundaram A, Srinivasan A, Baker S, et al. Readmission and risk factors for readmission following esophagectomy for esophageal cancer. J Gastrointest Surg. 2015;19:581-585; discussion 586.
12. Bhagat R, Bronsert MR, Juarez-Colunga E, et al. Postoperative Complications Drive Unplanned Readmissions After Esophagectomy for Cancer. Ann Thorac Surg. 2018;105:1476-1482.
13. Kassin MT, Owen RM, Perez SD, et al. Risk factors for 30-day hospital readmission among general surgery patients. J Am Coll Surg. 2012;215:322-330.
14. Doorakkers E, Konings P, Mattsson F, et al. Early complications following oesophagectomy for cancer in relation to long-term healthcare utilisation: a prospective population-based cohort study. PLoS One 2015;10:e0121080. doi: 10.1371/journal.pone.0121080. eCollection 2015.
15. Jiang R, Liu Y, Ward KC, et al. Excess Cost and Predictive Factors of Esophagectomy Complications in the SEER-Medicare Database. Ann Thorac Surg. 2018;106:1484-1491.
16. Low DE, Kuppusamy M, Hashimoto Y, et al. Comparing complications of esophagectomy and pancreaticoduodenectomy and potential impact on hospital systems utilizing the accordion severity grading system. J Gastrointest Surg. 2010;14:1646-1652.
17. Kauppila JH, Johar A, Lagergren P. Postoperative Complications and Health-related Quality of Life 10 Years After Esophageal Cancer Surgery. Ann Surg. 2020;271:311-316.
18. Scarpa M, Saadeh LM, Fasolo A, et al. Health-related quality of life in patients with oesophageal cancer: analysis at different steps of the treatment pathway. J Gastrointest Surg. 2013;17:421-433.
19. Low DE, Kuppusamy MK, Alderson D, et al. Benchmarking Complications Associated with Esophagectomy. Ann Surg. 2019;269:291-298.

20. Carroll PA, Jacob N, Yeung JC, et al. Using Benchmarking Standards to Evaluate Transition to Minimally Invasive Esophagectomy. Ann Thorac Surg. 2020;109:383-388.

21. Reynolds JV, Preston SR, O'Neill B, et al. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401.

22. van der Werf LR, Busweiler LAD, van Sandick JW, et al. Reporting National Outcomes After Esophagectomy and Gastrectomy According to the Esophageal Complications Consensus Group (ECCG). Ann Surg. 2019. doi: 10.1097/SLA.0000000000003210. [Epub ahead of print]

23. Low DE, Alderson D, Cecconello I, et al. International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg. 2015;262:286-294.

24. Etzioni DA, Wasif N, Dueck AC, et al. Association of hospital participation in a surgical outcomes monitoring program with inpatient complications and mortality. JAMA 2015;313:505-511.

25. Koch CG, Li L, Hixson E, et al. What are the real rates of postoperative complications: elucidating inconsistencies between administrative and clinical data sources. J Am Coll Surg. 2012;214:798-805.

26. Lapar DJ, Stukenborg GJ, Lau CL, et al. Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. J Thorac Cardiovasc Surg. 2012;144:1152-1157.

27. Low DE, Allum W, De Manzoni G, et al. Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS((R))) Society Recommendations. World J Surg. 2019;43:299-330.

28. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. National Comprehensive Cancer Network. Available at

https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Version 2.2019 – May 29, 2019, Accessed: March 9, 2020.

29. Kataoka K, Takeuchi H, Mizusawa J, et al. Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer: Exploratory Analysis of JCOG9907. Ann Surg. 2017;265:1152-1157.

30. Goel NJ, Iyengar A, Kelly JJ, et al. Nationwide Analysis of 30-Day Readmissions After Esophagectomy: Causes, Costs, and Risk Factors. Ann Thorac Surg. 2020;109:185-193.

31. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887-1892.

32. Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. N Engl J Med. 2019;380:152-162.

33. van der Sluis PC, van der Horst S, May AM, et al. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial. Ann Surg. 2019;269:621-630.

34. Kamarajah SK, Lin A, Tharmaraja T, et al. Risk factors and outcomes associated with anastomotic leaks following esophagectomy: a systematic review and meta-analysis. Dis Esophagus 2020;33. pii: doz089. doi: 10.1093/dote/doz089.

35. Fransen LFC, Berkelmans GHK, Asti E, et al. The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study. Ann Surg. 2020 Jan 14. doi: 10.1097/SLA.0000000000003772. [Epub ahead of print]

36. Hall BR, Flores LE, Parshall ZS, et al. Risk factors for anastomotic leak after esophagectomy for cancer: A NSQIP procedure-targeted analysis. J Surg Oncol. 2019;120:661-669.

37. Srinivasa S, Gurney J, Koea J. Potential Consequences of Patient Complications for Surgeon Well-being: A Systematic Review. JAMA Surg. 2019;154:451-457.

38. Fernandez FG, Khullar O, Force SD, et al. Hospital readmission is associated with poor survival after esophagectomy for esophageal cancer. Ann Thorac Surg. 2015;99:292-297.

39. Park SY, Kim DJ, Byun GE. Incidence and risk factors of readmission after esophagectomy for esophageal cancer. J Thorac Dis. 2019;11:4700-4707.

40. Hu Y, McMurry TL, Stukenborg GJ, et al. Readmission predicts 90-day mortality after esophagectomy: Analysis of Surveillance, Epidemiology, and End Results Registry linked to Medicare outcomes. J Thorac Cardiovasc Surg. 2015;150:1254-1260.

41. Centers for Medicare and Medicaid Services. Readmissions Reducton Program. Available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program; 2016. Accessed March 2, 2020.

42. Boshier PR, Ziff C, Adam ME, et al. Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer: a systematic review and meta-analysis. Dis Esophagus 2018;31. doi: 10.1093/dote/dox134.

43. Reeh M, Ghadban T, Dedow J, et al. Allogenic Blood Transfusion is Associated with Poor Perioperative and Long-Term Outcome in Esophageal Cancer. World J Surg. 2017;41:208-215.

44. Komatsu Y, Orita H, Sakurada M, et al. Intraoperative blood transfusion contributes to decreased long-term survival of patients with esophageal cancer. World J Surg. 2012;36:844-850.

45. Lee J, Chin JH, Kim JI, et al. Association between red blood cell transfusion and long-term mortality in patients with cancer of the esophagus after esophagectomy. Dis Esophagus 2018 Feb 1;31. doi: 10.1093/dote/dox123.

46. Kaufmann KB, Baar W, Glatz T, et al. Epidural analgesia and avoidance of blood transfusion are associated with reduced mortality in patients with postoperative pulmonary complications following thoracotomic esophagectomy: a retrospective cohort study of 335 patients. BMC Anesthesiol. 2019;19:162.

47. Towe CW, Gulack BC, Kim S, et al. Restrictive Transfusion Practices After Esophagectomy Are Associated With Improved Outcome: A Review of the Society of Thoracic Surgeons General Thoracic Database. Ann Surg. 2018;267:886-891.

48. Dixon E, Datta I, Sutherland FR, et al. Blood loss in surgical oncology: neglected quality indicator? J Surg Oncol. 2009;99:508-512.

49. Hii MW, Smithers BM, Gotley DC, et al. Impact of postoperative morbidity on long-term survival after oesophagectomy. Br J Surg. 2013;100:95-104.

Special Acknowledgements

All Members of the IESG wish to provide particular thanks to the Hayward Family Foundation, particularly Admiral Thomas Hayward, his wife Peggy Hayward and two daughters Cynthia Hayward and Colleen Smith. The creation and maintenance of the Esodata.org database would not have been possible without their assistance.

Special acknowledgement should also be made to Ms. Bonnie Marston for administrative and manuscript support, and to Dr. Fredrik Klevebro and Dr. Francesco Puccetti for their invaluable assistance in data management and statistical review.

IESG – Authors and Study Contributors

INSTITUTION	LEAD	OTHER INSTITUTIONAL CONTRIBUTORS
1. Agaplesion Markus Krankenhaus, Frankfurt, Germany	Arnulf Hoelscher	Stephen Minot
2. Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands	Mark I. van Berge Henegouwen Suzanne S. Gisbertz	Egle Jezerskyte Wietse J. Eshuis
3. Cambridge Oesophago-Gastric Centre, Addenbrookes Hospital, Cambridge, UK	Richard Hardwick Peter Safranek	
4. Claude Huriez University Hospital, Lille, France	Guillaume Piessen	Marguerite Messier Sébastien Degisors Friederiek Nuytens Christophe Mariette
5. Erasmus Medical Center, Rotterdam, Netherlands	Jan van Lanschot Bas Wijnhoven	Sjoerd M. Lagarde
6. Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA	Blair Jobe	Ali H. Zaidi
7. Guy's & St Thomas' NHS Foundation Trust, London, UK	Andrew Davies	Janine Zylstra James Gossage Cara Baker Mark Kelly
8. Hirslanden Medical Center, Zürich, Switzerland	Paul M. Schneider	Simone Schillinger
9. Hôpital Nord, Aix-Marseille Université, Marseille, France	Xavier Benoit D'Journo	
10. Hospital Universitario del Mar, Barcelona, Spain	Manuel Pera	Marta Gimeno
11. Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden	Magnus Nilsson Fredrik Klevebro	Masaru Hayami
12. Katholieke Universiteit Leuven, Leuven, Belgium	Philippe Nafteux Toni Lerut	Johnny Moons
13. Keio University, Tokyo, Japan	Yuko Kitagawa	Hirofumi Kawakubo Satoru Matsuda Yuki Hirata
14. Massachusetts General Hospital, Boston, MA, USA	Christopher R. Morse	Julie Garrity
15. MD Anderson Cancer Center, Houston, TX, USA	Wayne Hofstetter	Huawei Tang
16. Memorial Sloan Kettering Cancer Center, New York City, NY, USA	Daniela Molena	Manjit Bains Joe Dycoco Kristen Busalacchi Rebecca Carr David R. Jones
17. National University Hospital, Singapore, Singapore	Jimmy So Bak Yan	Asim Shabbir
18. Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK	Arul Immanuel Michael Griffin	Helen Jaretzke
19. Nottingham University Hospitals NHS Trust, Nottingham, UK	Simon L. Parsons	Neil T. Welch Ravinder Vohra James A. Catton John H. Saunders Fady Yanni Daniela Zanotti Pritam Singh
20. Odense University Hospital, Odense, Denmark	Michael Hareskov Larsen	Nicolaj Marcus Stilling
21. Oregon Health and Science University, Portland, OR, USA	James P. Dolan	Charlie C. Borzy Kayla Siemens
22. Oxford University Hospitals NHS Foundation Trust, Oxford, UK	Nick Maynard	John Findlay Stephen Ash
23. Princess Alexandra Hospital, University of Queensland, Brisbane, Australia	Mark Smithers Iain Thomson	Andrew Barbour Janine Thomas

IESG – Authors and Study Contributors

INSTITUTION	LEAD	OTHER INSTITUTIONAL CONTRIBUTORS
24. Queen Elizabeth Hospital University of Birmingham, Birmingham, UK	Sonia Puig Derek Alderson	John Whiting
25. Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China	Simon Law Ian Wong	Jeannette Kwok
26. Royal Victoria Hospital, Belfast, Northern Ireland	Andrew Kennedy	Raymond Kennedy
27. Sichuan Cancer Hospital & Institute, Chengdu, China	Wang KangNing	Fang Qiang Han YongTao Peng Lin Xiao WenGuang
28. St. James's Hospital Trinity College, Dublin, Ireland	John V. Reynolds	Sinead King Ravi Narayanasamy
29. Tata Memorial Centre, Mumbai, India	C.S. Pramesh	Apurva Ashok
30. The University of Chicago Medicine, Chicago, IL, USA	Mark Ferguson	Amy Durkin-Celauro Catherine Staub
31. Toronto General Hospital, Toronto, Canada	Gail Darling	Emma Small
32. University Hospital of Cologne, Cologne, Germany	Wolfgang Schröder Marc Bludau	Antonia Frebel
33. University Hospital Southampton NHS Foundation Trust, Southampton, UK	Tim Underwood	James Byrne Jamie Kelly Fergus Noble Donna Sharland Rachel Fraser Rob Walker Saqib Rahman Ben Grace
34. University Medical Center, Utrecht, Netherlands	Richard van Hillegersberg Jelle Ruurda	Sylvia van der Horst Arjen van der Veen Gino Kuiper
35. University of Michigan Health System, Ann Arbor, MI, USA	Andrew Chang	Judy Miller Shari Barnett
36. University of São Paulo School of Medicine, São Paulo, Brazil	Ivan Cecconello Ulysses Ribeiro, Jr.	Rubens A. A. Sallum
37. University of Verona, Verona, Italy	Giovanni de Manzoni Jacopo Weindelmayer	Carlo Alberto De Pasqual
38. Virginia Mason Medical Center	Donald E. Low MadhanKumar Kuppusamy	
39. Vita-Salute San Raffaele University, Milan, Italy	Riccardo Rosati Paolo Parise	Andrea Cossu Francesco Puccetti Simonetta Massaron

Special Acknowledgements

All Members of the IESG wish to provide particular thanks to the Hayward Family Foundation, particularly Admiral Thomas Hayward, his wife Peggy Hayward and two daughters Cynthia Hayward and Colleen Smith. The creation and maintenance of the Esodata.org database would not have been possible without their assistance.

Special acknowledgement should also be made to Ms. Bonnie Marston for administrative and manuscript support, and to Dr. Fredrik Klevebro and Dr. Francesco Puccetti for their invaluable assistance in data management and statistical review.

SUPPLEMENT 1

Membership Agreement Signed at the Time of Registration on the ESODATA Website Documenting the Responsibility of Contributing Institutions

ESODATA.org
Membership Agreement

I WILL take part in the analysis and production of manuscripts based on the results of the ESODATA.org data collection.

I WILL NOT share the results of the interim reports sent from esodata.org until formally reviewed for publication by the ISDE-appointed Research and Database Committee.

I WILL comply and fulfill all institutional and national criteria for participation in this study.

I WILL record all patients undergoing esophageal resection at my institution that fulfill the criteria for inclusion during the study period.

I WILL record information accurately, completely and in a timely fashion on the www.esodata.org data collection I will promptly respond to email/correspondence requests for information, data update or opinion to maintain consensus during the study period.

I WILL ensure that data entered is fully anonymized and no identifiable patient information is entered in esodata.org database.

BY SIGNING THIS DOCUMENT, I accept ESODATA.org membership and agree to adhere to all the responsibilities of the Membership Agreement.

_____

Signature

Table 1. Esodata Contributing Centers 2015-2018

Countries: 19	**Institutions: 39**
Australia	Princess Alexandra Hospital, University of Queensland
Belgium	Katholieke Universiteit Leuven
Brazil	University of São Paulo School of Medicine
Canada	Toronto General Hospital
China	Queen Mary Hospital, The University of Hong Kong Sichuan Cancer Hospital & Institute
Denmark	Odense University Hospital
France	Claude Huriez University Hospital Hôpital Nord, Aix-Marseille Université
Germany	Agaplesion Markus Krankenhaus University Hospital of Cologne
India	Tata Memorial Centre
Ireland	St. James's Hospital Trinity College
Italy	University of Verona Vita-Salute San Raffaele University
Japan	Keio University
The Netherlands	Amsterdam UMC, University of Amsterdam Erasmus Medical Center University Medical Center
Singapore	National University Hospital
Spain	Hospital Universitario del Mar
Sweden	Karolinska Institutet and Karolinska University Hospital
Switzerland	Hirslanden Medical Center
United Kingdom	Cambridge Oesophago-Gastric Centre, Addenbrookes Hospital Nottingham University Hospitals NHS Trust Oxford University Hospitals NHS Foundation Trust Queen Elizabeth Hospital University of Birmingham Royal Victoria Hospital Guy's & St Thomas' NHS Foundation Trust Newcastle Upon Tyne Hospitals University Hospital Southampton NHS Foundation Trust
USA	Esophageal and Lung Institute, Allegheny Health Network Massachusetts General Hospital MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Oregon Health and Science University The University of Chicago Medicine University of Michigan Health System Virginia Mason Medical Center

Table 2. Patient Demographics

N (%)	2015-2016	2017-2018	ALL PATIENTS	P-value
Sex				0.088
Female	614 (22.7%)	693 (20.9)	1307 (21.7%)	
Male	2090 (77.3%)	2625 (79.1)	4715 (78.3%)	
Mean Age, yrs	63.0	63.5	63.2	0.035
Age group, yrs				0.015
40 or less	66 (2.4%)	89 (2.7%)	155 (2.6%)	
41–50	230 (8.5%)	266 (8.0%)	496 (8.2)	
51–60	706 (26.1%)	787 (23.7%)	1493 (24.8)	
61–70	1091 (40.4%)	1313 (39.6%)	2404 (39.9)	
71–80	540 (20.0%)	785 (23.7%)	1325 (22.0)	
More than 80	71 (2.6%)	78 (2.4%)	149 (2.5)	
BMI group				<0.001
<18.5	184 (6.8%)	140 (4.2%)	324 (5.4%)	<0.001
18.5–25	1027 (38.0%)	1290 (38.9%)	2317 (38.5)	
25–30	929 (34.4%)	1214 (36.6%)	2143 (35.6%)	
30-35	395 (14.6%)	462 (13.9%)	857 (14.2%)	
>35	169 (6.3%)	212 (6.4)	381 (6.3%)	
ACCI score groups				0.571
0–3	751 (27.8%)	884 (26.6%)	1635 (27.2)	
4–7	1872 (69.2%)	2321 (70.0%)	4193 (69.9)	
8–11	74 (2.7%)	106 (3.2%)	180 (3.0)	
12 and above	7 (0.3%)	7 (0.2%)	14 (0.2)	
ASA status score				<0.001
1	428 (15.8%)	373 (11.2%)	801 (13.3%)	
2	1256 (46.5%)	1410 (42.5%)	2666 (44.3%)	
3	947 (35.0%)	1459 (44.0%)	2406 (40.0)	<0.001
4	69 (2.6%)	75 (2.3%)	144 (2.4%)	
5	4 (0.2%)	1 (0.0%)	5 (0.1%)	
WHO/ECOG performance				<0.001
0	1503 (55.6%)	1515 (45.7%)	3018 (50.1%)	<0.001
1	1054 (39.0%)	1583 (47.7%)	2637 (43.8%)	
2	133 (4.9%)	158 (4.8%)	291 (4.8%)	
3	11 (0.4%)	56 (1.7%)	67 (1.1%)	
4	3 (0.1%)	6 (0.2%)	9 (0.2%)	

Table 3. Demographics – Pathology and Operative Approach

N (%)	2015-2016	2017-2018	ALL PATIENTS	P-value
Pathology (indication for surgery)				0.058
Benign	90 (3.3%)	77 (2.3%)	167 (2.8%)	
Malignant	2597 (96.0%)	3222 (97.1%)	5819 (96.6)	
Others, including perforations	17 (0.6%)	19 (0.6%)	36 (0.6%)	
Tumor location				<0.001
At the GE junction	758 (29.2%)	1211 (37.6%)	1969 (33.8%)	
Proximal 1/2 of esophagus	311 (12.0%)	374 (11.6%)	685 (11.8%)	
Distal 1/2 of esophagus	1528 (58.8%)	1637 (50.8%)	3165 (54.4%)	
Surgical approach				<0.001
Minimally invasive	1297 (48.0%)	1880 (56.7%)	3177 (52.8%)	
Open	1407 (52.0%)	1438 (43.3%)	2845 (47.2%)	
Open esophagectomy				0.256
Transhiatal	290 (20.6%)	322 (22.4%)	612 (21.5%)	
Transthoracic	1117 (79.4%)	1118 (77.6%)	2235 (78.5%)	
Minimally invasive esophagectomy				<0.001
Abdomen only	485 (37.4%)	752 (40.0%)	1237 (38.9%)	
Chest only	135 (10.4%)	119 (6.3%)	254 (8.0%)	
Abdomen and chest	677 (52.2%)	1009 (53.7%)	1686 (53.1%)	
Site of anastomosis				0.003
Chest	1661 (61.4%)	2177 (65.6%)	3838 (63.7%)	
Neck	1010 (37.4%)	1108 (33.4%)	2118 (35.2%)	
Others/None	33 (1.2%)	33 (1.0%)	66 (1.1%)	
Esophageal conduit				0.695
Stomach	2581 (95.5%)	3185 (96.0%)	5766 (95.8%)	
Colon	34 (1.3%)	34 (1.0%)	68 (1.1%)	
Small bowel	64 (2.4%)	68 (2.1%)	132 (2.2%)	
Others/None	25 (0.9%)	31 (0.9%)	56 (0.9%)	
Lymphadenectomy neck				0.296
No	2295 (91.6%)	2552 (92.4%)	4847 (92.0%)	
Yes	211 (8.4%)	211 (7.6%)	422 (8.0%)	
Resection margins				0.380
R0 – Negative	2417 (93.1%)	3024 (93.9%)	5441 (93.5%)	
R1 – Microscopic positive	163 (6.3%)	175 (5.4%)	338 (5.8%)	
R2 – Macroscopic positive	17 (0.7%)	23 (0.7%)	40 (0.7%)	
Neoadjuvant treatment				<0.001
None	581 (22.4)	633 (19.7)	1214 (20.9%)	
Neoadjuvant chemotherapy	833 (32.1)	792 (24.6)	1625 (27.9%)	
Neoadjuvant chemoradiotherapy	1099 (42.3)	1735 (53.9)	2834 (48.7%)	
Definitive chemoradiotherapy	80 (3.1)	56 (1.7)	136 (2.3%)	
Hospital Stay (days)	17.3	16.7	17.0	0.138

Table 4. ECCG Complication Outcomes: Entire Study Group and Trends in Complications Over Time

N, % (95% CI)	2015-2016	2017-2018	ALL PATIENTS	P-value
GASTROINTESTINAL – OVERALL INCIDENCE	**610 22.6%**	**815 (24.6%)**	**1425 23.7%**	**0.069**
Esophagoenteric leak from anastomosis, staple line, or localized conduit necrosis	317 11.7% (10.2-12.6)	433 (13.1)	750 12.5% (11.6-13.3)	0.121
Conduit necrosis/failure requiring surgery	33 1.2%	41 (1.2%)	74 1.2% (1.0-1.5)	0.957
Ileus defined as small bowel dysfunction preventing or delaying enteral feeding	49 1.8%	36 (1.1%)	85 1.4% (1.1-1.7)	0.017
Small bowel obstruction	15 0.6%	12 (0.4%)	27 0.5% (0.3-0.7)	0.265
Feeding J-tube complication	33 1.2%	70 (2.1%)	103 1.7% (1.4-2.1)	0.008
Pyloromyotomy/Pyloroplasty complication	4 0.2%	5 (0.2%)	9 0.2% (0.1-0.3)	0.978
Clostridium difficile infection	27 1,0%	29 (0.9%)	56 0.9% (0.7-1.2)	0.617
Pancreatitis	9 0.3%	5 (0.2%)	14 0.2% (0.1-0.4)	0.144
GI bleeding requiring intervention or transfusion	28 1.0%	16 (0.5%)	44 0.7% (0.5-1.0)	0.012
Liver dysfunction	7 0.3%	14 (0.4%)	21 0.4% (0.2-0.5)	0.286
Delayed conduit emptying requiring intervention or delaying discharge or requiring maintenance of NG drainage >7 days post-op	159 5.9%	221 (6.7%)	380 6.3% (5.7-7.0)	0.215
PULMONARY	**784 29.0%**	**838 (25.3%)**	**1622 26.9%**	**0.001**
Pneumonia	414 15.3%	424 (12.8%)	838 13.9%	0.005
Pleural effusion requiring additional drainage procedure	264 9.8%	263 (7.9%)	527 8.8%	0.012
Pneumothorax requiring intervention	92 3.4%	85 (2.6%)	177 2.9%	0.055
Atelectasis mucous plugging requiring bronchoscopy	86 3.2%	74 (2.2%)	160 2.7%	0.023
Respiratory failure requiring reintubation	190 7.0%	214 (6.5%)	404 6.7%	0.373
Acute respiratory distress syndrome	57 2.1%	69 (2.1%)	126 2.1%	0.939
Acute aspiration	22 0.8%	40 (1.2%)	62 1.0%	0.134
Tracheobronchial injury	13 0.5%	6 (0.2)	19 0.3%	0.039
Chest drain requirement for air leak for >10 d post-op	12 0.4%	17 (0.5%)	29 0.5%	0.702
CARDIAC	**459 17.0%**		**1013 16.8%**	
Cardiac arrest requiring CPR	24 0.9% (0.6-1.3)	24 (0.7%)	48 0.8%	0.476
Myocardial infarction	15 0.6%	16 (0.5%)	31 0.5%	0.696
Atrial dysrhythmia requiring intervention	400 14.8%	487 (14.7%)	887 14.7	0.900
Ventricular dysrhythmia requiring intervention	23 0.9%	32 (1.0%)	55 0.9%	0.644
Congestive heart failure requiring intervention	11 0.4%	15 (0.5%)	26 0.4%	0.790
Pericarditis requiring intervention	3 0.1%	9 (0.3%)	12 0.2%	0.165
Thromboembolic	67 2.5%	94 (2.8%)	161 (2.7%)	0.395
DVT	26 0.0%	31 (0.9%)	57 1.0%	0.914
PE	33 1.2%	55 (1.7)	88 1.5%	0.160
Stroke	4 0.2%	8 (0.2%)	12 0.2%	0.420
Peripheral thrombophlebitis	5 0.2%	9 (0.3%)	14 0.2%	0.489
UROLOGIC	**234 8.7%**		**421 7.0%**	
Acute renal insufficiency (defined as doubling of baseline creatinine)	40 1.5%	45 (1.4%)	85 1.4%	0.687
Acute renal failure requiring dialysis	26 1.0%	13 (0.4%)	39 0.7%	0.006
Urinary tract infection	78 2.9%	51 (1.5%)	129 2.1%	<0.001
Urinary retention requiring reinsertion of urinary catheter, delaying discharge, or discharge w/urinary catheter	102 3.8%	86 (2.6%)	188 3.1%	0.009
INFECTION	**172 (6.4%) 14.2%**	**297 (9.0%)**	**469 7.8%**	**<0.001**
Wound infection requiring opening wound or antibiotics	9 0.3%	153 (4.6%)	162 2.7%	<0.001
Central IV line infection requiring removal or antibiotics	52 1.9%	34 (1.0%)	86 1.4%	0.003
Intrathoracic/Intra-abdominal abscess	64 2.4%	56 (1.7%)	120 2.0%	0.061
Generalized sepsis	59 2.2%	76 (2.3%)	135 2.2%	0.777
Other infections requiring antibiotics	212 7.8%	202 (6.1%)	414 6.9%	0.008
NEUROLOGIC/PSYCHIATRIC	**275 10.2%%**	**258 (7.8%)**	**533 8.9%**	**0.001**
Recurrent nerve injury	131 4.8%	133 (4.0%)	264 4.4%	0.115
Other neurologic injury	38 1.4%	6 (0.2%)	44 0.7%	<0.001
Acute delirium	105 3.9%	118 (3.6%)	223 3.7%	0.504
Delirium tremens	15 0.6%	6 (0.2%)	21 0.4%	0.014
WOUND/DIAPHRAGM	**82 3.0%**	**58 (1.8%)**	**140 2.3%**	**0.001**
Thoracic wound dehiscence	43 1.6%	27 (0.8%)	70 1.2%	0.005
Acute abdominal wall dehiscence/hernia	34 1.3%	25 (0.8%)	59 1.0%	0.048
Acute diaphragmatic hernia	8 0.3%	8 (0.2%)	16 0.3%	0.681
OTHER COMPLICATIONS	**194 7.2%**	**212 (6.4%)**	**406 6.7%**	**0.227**
Chyle leak	137 (5.1%)	141 (4.3%)	278 4.6%	0.133
Reoperation for reasons other than anastomotic leak or conduit necrosis	40 1.5%	46 (1.4%)	100 1.7%	0.762
Multiple organ dysfunction syndrome	26 1.0%	19 (0.6%)	45 0.8%	0.081

Table 5. Complications: Overall Incidence and Incidence of Multiple Complications

N, N% (95% CI)	**2015-2016**	**2017-2018**	**ALL PATIENTS**	**P-value**
Complications				0.320
No	1087 40.2% (38.4-42.1)	1292 38.9% (37.3-40.6)	2379 39.5% (38.2-40.7)	
Yes	1617 59.8% (57.9-61.6)	2026 61.1% (59.4-62.7)	3643 60.5% (59.3-61.7)	
Number of complications in each patient				<0.001
0	1087 (40.2%)	1292 (38.9%)	2379 39.5% (38.2-40.7)	
1	704 (26.0%)	1019 (30.7%)	1723 28.6% (27.5-29.8)	
2	426 (15.8%)	500 (15.1%)	926 15.4% (14.5-16.3)	
3	229 (8.5%)	264 (8.0%)	493 8.2% (7.5-8.9)	
4 or more	258 (9.5%)	243 (7.3%)	501 8.3% (7.6-9.0)	
Clavien-Dindo score				<0.001
Grade I	259 (9.6%%)	222 (6.7%)	481 (8.0%)	
Grade II	611 (22.6%)	805 (24.3%)	1416 (23.5%)	
Grade IIIa	375 (13.9%)	542 (16.3%)	917 (15.2%)	
Grade IIIb	195 (7.2%)	237 (7.1%)	432 (7.2%)	
Grade IVa	170 (6.3%)	225 (6.8%)	395 (6.6%)	
Grade IVb	39 (1.4%)	35 (1.1%)	74 (1.2%)	
Grade V	69 (2.6%)	74 (2.2%)	143 (2.4%)	
Grade > IIIb	473 (17.5%)	571 (17.2%)	1044 (17.3)	0.773

Table 6. Quality Measure Outcomes: Entire Study Group and Trends Over Time

N, N% (95% CI)	2015-2016	2017-2018	ALL PATIENTS	P-value
Readmission within 30 days of discharge				<0.001
No readmission	2266 (86.0%)	2836 (87.6%)	5102 (86.9%)	
Readmission related to esophagectomy	292 (11.1%)	275 (8.5%)	567 (9.7%)	
Unrelated readmission	31 (1.2%)	31 (1.0%)	62 (1.1%)	
Readmissions status not known	46 (1.8%)	94 (2.9%)	140 (2.4%)	
Not discharged at 30 days or died inpatient	71 (2.6%)	82 (2.5%)	153 (2.5%)	
Perioperative mortality				
Alive after 30 days post-op but died before 90 days	56 (2.1%)	68 (2.1%)	128 (2.1%)	0.650
Alive after 90 days post-op	2574 (95.7%)	2773 (95.4%)	5347 (88.8%)	0.679
Died within 30 days post-op	65 (2.4%)	65 (2.0%)	122 (2.0%)	0.683
90-day mortality	117 (4.4%)	133 (4.6%)	250 (4.5%)	0.679
Status not known/lost to follow-up after 30 days post discharge	2 (0.1%)	27 (0.8%)	29 (0.5%)	<0.001
Blood utilization				<0.001
No transfusions	2320 (85.8%)	2979 (89.8%)	5299 (89.0%)	
Intraoperative transfusion	53 (2.0%)	45 (1.4%)	98 (1.6%)	
Postoperative transfusion	297 (11.0%)	273 (8.2%)	570 (9.5%)	
Intra- and postoperative transfusion	34 (1.3%)	21 (0.6%)	55 (0.9%)	
Readmissions				
No readmission	2266 (83.8%)	2836 (85.5%)	5102 (84.7%)	
Readmission related to esophagectomy	292 (10.8%)	275 (8.3%)	567 (9.4%)	
Unrelated readmission	31 (1.2%)	31 (0.9%)	62 (1.0%)	
Unknown	115 (4.3%)	176 (5.3%)	291 (4.8%)	
Level of care escalation				<0.001
Yes	663 (24.5%)	665 (20.0%)	1328 (22.1%)	
No	2041 (75.5%)	2653 (80.0%)	4694 (78.0%)	
Discharged home				<0.001
No	234 (8.7%)	405 (12.2%)	639 (10.6%)	
Yes	2470 (91.4%)	2913 (87.8%)	5383 (89.4%)	

P-values comparing 2015-2016 cohort to 2017-2018.

Table 7. Outcomes of ECCG Complications

N (%)	2015-2016	2017-2018	ALL PATIENTS	P-value
Anastomotic leak				
No anastomotic leak	2387 (88.3%)	2885 (87.0%)	5272 (87.6%)	0.121
Type of leak				0.003
Type I:	99 (3.7%)	109 (3.3%)	208 (3.5%)	
Type II:	120 (4.4%)	223 (6.7%)	343 (5.7%)	
Type III:	89 (3.3%)	101 (3.0)	190 (3.2%)	
Unknown type of leak	9 (0.3%)	0 (0%)	9 (0.2%)	
Conduit necrosis				
No conduit necrosis	2671 (98.8%)	3277 (98.8)	5948 (98.8%)	0.957
Type of conduit necrosis				0.576
Type I:	2 (0.1%)	5 (0.2%)	7 (0.1%)	
Type II:	6 (0.2%)	10 (0.3%)	16 (0.3%)	
Type III:	23 (0.9%)	26 (0.8%)	49 (0.8%)	
Unknown type of conduit necrosis	2 (0.1%)	0 (0%)	2 (0.0%)	
Recurrent laryngeal nerve injury				
No injury	2573 (95.2%)	3185 (96.0%)	5758 (95.6%)	0.115
Type of injury				0.797
Type Ia:	88 (3.3%)	99 (3.0%)	187 (3.1%)	
Type Ib:	8 (0.3%)	6 (0.2%)	14 (0.2%)	
Type IIa:	14 (0.5%)	19 (0.6%)	33 (0.6%)	
Type IIb:	4 (0.2%)	3 (0.1%)	7 (0.1%)	
Type IIIa:	3 (0.1%)	1 (0.0%)	4 (0.1%)	
Type IIIb:	5 (0.2%)	5 (0.2%)	9 (0.2%)	
Unknown type of nerve injury	9 (0,3%)	0	9	
Chyle leak				
No chyle leak	2567 (94.9%)	3177 (95,8%)	5744 (95.4%)	0,133
Type of chyle leak				0.043
Type Ia:	74 (2.7%)	64 (1.9%)	138 (2.3%)	
Type Ib:	7 (0.3%)	6 (0.2%)	13 (0.2%)	
Type IIa:	13 (0.5%)	10 (0.3%)	23 (0.4%)	
Type IIb:	8 (0.3%)	10 (0.3%)	18 (0.3%)	
Type IIIa:	16 (0.6%)	12 (0.4%)	28 (0.5%)	
Type IIIb:	16 (0.6%)	39 (1.2%)	55 (0.9%)	
Unknown type of chyle leak	3 (0.1%)	0 (0%)	3	

DEFINITIONS

ANASTOMOTIC LEAK: Full thickness GI defect involving esophagus, anastomosis, staple line, or conduit irrespective of presentation or method of identification

Grade I Local defect requiring no change in therapy or treated medically or with dietary modification
Grade II Localized defect requiring interventional but not surgical therapy, e.g., IR drain, stent or bedside opening and packing of incision
Grade III Localized defect requiring surgical therapy

CONDUIT NECROSIS: Full thickness GI defect involving esophagus, anastomosis, staple line, or conduit irrespective of presentation or method of identification

Grade I Conduit necrosis focal; Identified endoscopically
Treatment – Additional monitoring or non-surgical therapy
Grade II Conduit necrosis focal; Identified endoscopically and not associated with free anastomotic or conduit leak
Treatment – Surgical therapy not involving esophageal diversion
Grade III Conduit necrosis extensive
Treatment – Treated with conduit resection with diversion

RECURRENT LARYNGEAL NERVE INJURY: Vocal cord dysfunction post-resection. Confirmation and assessment should be by direct examination

Grade I Transient injury requiring no therapy; dietary modification allowed
Grade II Injury requiring elective surgical procedure, e.g., thyroplasty or medialization procedure
Grade III Injury requiring acute surgical intervention (due to aspiration or respiratory issues), e.g., thyroplasty or medialization procedure
Severity Level a) Unilateral b) Bilateral

E.g., A unilateral vocal cord injury requiring elective medialization procedure. Final Grade IIA

CHYLE LEAK: Milky discharge upon initiation of enteric feeds and/or pleural fluid analysis demonstrating triglyceride level >100 mg/dl and/or chylomicrons in pleural fluid

Grade I Treatment – enteric dietary modifications
Grade II Treatment – total parenteral nutrition
Grade III Treatment – interventional or surgical therapy**
Severity Level a) < 1 liter output/day b) > 1 liter output/day

E.g., a chyle leak initially producing 1200 ml/day and successfully treated by stopping enteric feeds and initiating TPN. Final Grade IIB

** NOTE: Does not include elective insertion of additional surgical or interventional chest drains